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The purpose of this report is to highlight our experience with transcaval embolization (TCE) for the management of type
II endoleaks (T2Es) as well as to provide a technical description of how to improve procedural safety and success. All
patients underwent transfemoral venous access with transcaval puncture into the excluded aneurysm sac with coil
placement and selective thrombin injection. Six patients (100% male; mean age [standard deviation] 72.7 [10.8] years)
underwent TCE. Technical success was 100% with no postoperative complications. At median follow-up of 8.1 months
(range, 2-22 months), two patients had persistent T2Es, with one requiring repeat TCE and the other having cessation of
aneurysm growth. The TCE provides a practical alternative to transarterial or translumbar access for the management of
T2E, with high degrees of technical and clinical success in this small case series. Larger patient numbers and longer-term
follow-up are needed to deﬁne procedural efﬁcacy and durability. (J Vasc Surg 2013;57:869-74.)Although debate exists about when to intervene upon
type II endoleak (T2E) after endovascular aortic repair
(EVAR), several techniques have been described for the
management of this problem. Frequently, superior mesen-
teric or internal iliac artery collaterals to the inferior
mesenteric artery or lumbar arteries are accessed to deliver
the embolant; however, limitations of these approaches
include technical failure, difﬁculty in performance, and/
or recurrence in 20% to 80% of cases.1-3 Alternatively,
translumbar puncture has been shown to have more
durable success rates in >70% to 90% of patients beyond
8 months.4,5 Despite enthusiasm for a translumbar
approach, this technique often necessitates administration
of conscious sedation or general anesthesia, and success
depends on traversing multiple tissue planes with potential
risk of inadvertent injury to neighboring periaortic
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://dx.doi.org/10.1016/j.jvs.2012.09.021As a more direct alternative approach, transcaval
embolization (TCE) for the treatment of T2E has been
reported.6 The focus of this report is to describe our expe-
rience with TCE and to highlight the technical conduct of
the procedure.
METHODS
Clinical database and patient cohort. All patients
who underwent attempted TCE were identiﬁed. During
the study interval (2009-2012), 28 type II embolization
procedures were performed. Seven TCE procedures (in
six patients) were completed and constitute the study
cohort. The study was approved by the University of Flor-
ida Institutional Review Board.
A variety of commercially available endografts are used
in our practice, and device selection and implantation were
based upon the operating surgeon’s discretion and accord-
ing to the manufacturer’s instructions for use. Indications
for postoperative imaging were based on a predeﬁned
computed tomographic angiography (CTA) imaging
protocol (1- to 2-mm cuts) that included delayed venous
phased imaging at 1, 6, and 12 months and annually there-
after unless radiographic abnormalities, endoleak, or graft
integrity dictated otherwise.
Reintervention for T2E was undertaken if endoleak
persisted beyond 6 months and there was documented
increase ($5 mm) of aneurysm diameter on centerline
reconstruction (TeraRecon Inc, San Mateo, Calif). Tech-
nical success was deﬁned as the ability to gain catheter
access to the endoleak cavity and deliver embolant without869
Fig 1. A, Lateral aortic projection with the ring pediatric transjugular intrahepatic portosystemic shunt (TIPS) catheter
in place while a retrievable coil is delivered. The black arrow denotes the end of a Spectranetics Quick-Cross catheter
(Spectranetics Corporation, Colorado Springs, Colo) within the aneurysm sac with a 0.035-inch coil arising from the
catheter. The white arrows indicate coils placed at a previous intervention through a superior mesenteric artery to
inferior mesenteric artery approach that failed to obliterate the endoleak. The inset is an ex vivo picture of the pediatric
TIPS catheter with the guiding catheter and TIPS needle within the guiding sheath. B, Close approximation of the
inferior vena cava to the abdominal aortic aneurysm sac and a pediatric TIPS catheter in place delivering coils to the
abdominal aortic aneurysm sac.
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deﬁned as absence of endoleak on follow-up CTA and no
requirement for reintervention or further aneurysm growth.
Technical description. The TCE is performed in our
hybrid operating room using a percutaneous right transfe-
moral vein approach, with concomitant ipsilateral or
contralateral transfemoral arterial access for aortography.
All patients underwent TCE using local anesthesia with
light sedation. Aortography was performed to conﬁrm
the etiology/type of endoleak and to provide localization
relative to the existing endograft and inferior vena cava
(IVC). All procedures were performed using either a pedi-
atric ring or a Rösch-Uchida transjugular liver access set
(Cook Medical, Bloomington, Ind) through a 9F or 10F
(5F inner diameter) venous sheath (Fig 1, A, and inset).
Intravascular ultrasound within the IVC (9F; Volcano
Corp, San Diego, Calif) was selectively performed to
demonstrate proximity of the aortic aneurysm sac relative
to the IVC and to facilitate puncture.
Preoperative planning allows identiﬁcation of radio-
graphic markers on the stent graft or other landmarks
that may facilitate access to the endoleak (eg, graft bifurca-
tion, device overlap points, or aortic wall calciﬁcations) by
guiding transcaval puncture after the desired orientation of
the transjugular intrahepatic portosystemic shunt (TIPS)
assembly is conﬁrmed in two radiographic projections. A
transfemoral aortogram can also be performed to visualize
the endoleak and further guide alignment. In selected
cases, intraoperative ﬂat panel volume CT (Philips XperCT;
Philips, Andover, Mass) can be used to supplement theability to optimize needle orientation relative to the aneu-
rysm sac.
The common wall of the vena cava and aorta are punc-
tured with the TIPS needle, and a wire is advanced
through the needle into the aneurysm sac (Fig 1). Brisk
bleeding may be encountered upon entry into the endo-
leak, and injection of dye through the needle (sacogram)
can verify access. After the TIPS needle is removed,
a wire and catheter can be used to select the endoleak
cavity. We preferentially use 0.035- or 0.018-inch detach-
able coils, with the coil diameter dependent upon endoleak
cavity volume (estimated by sacography and CTA). Intra-
sac thrombin was used selectively if cessation of ﬂow was
not demonstrated after the endoleak cavity was ﬁlled
with coils.
After conﬁrmation of successful embolization by sacog-
raphy/aortography, the TIPS system is removed, and an
aortogram and vena cavogram are performed to determine
if there is evidence of aortocaval ﬁstula or contrast extrava-
sation. All patients were admitted overnight and underwent
noncontrast CT on the day of discharge to evaluate for
retroperitoneal hematoma. Follow-up CTA with delayed
venous phase imaging was performed 1 month after the
procedure (Fig 2) and then at intervals deﬁned by the
protocol after EVAR.
RESULTS
Six patients (100% male; mean age [standard deviation]
72.7 [10.8] years) underwent a total of seven TCE proce-
dures. Median follow-up time was 8.1 months (range,
Fig 2. Axial computed tomographic scan before (top panels) and after (bottom panels) transcaval embolization of a type
II endoleak. Note the close approximation of the inferior vena cava to the abdominal aortic aneurysm sac.
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speciﬁc details of previous EVAR and attempted emboliza-
tions are listed in Table I. Median time from EVAR to
TCE was 52 months (range, 17-98 months). During that
period, patients experienced a mean of 17.8 (11.9) mm
of aneurysm diameter enlargement.
Procedure-speciﬁc details of TCE are also listed in
Table I. The mean number of coils deployed was 7.3 (3.6).
Two patients had selective thrombin injection after multiple
coils failed to thrombose the endoleak. Intravascular ultra-
sound was used in four cases, and two patients underwent
intraoperative CT to guide catheter placement. Technical
success was 100%, and therewere no postoperative complica-
tions. Speciﬁcally, no evidence of retroperitoneal hematoma,
aortocaval ﬁstula, ormalpositioned embolantwas seenon any
early or late postoperative imaging.
Therapeutic outcomes. Clinical success was achieved
in four patients (66%). Two patients had persistent T2E,
with one showing no aneurysm growth at 6 months. The
other patient had persistent growth requiring repeat TCE
at 21 months. In the patient who underwent repeatTCE, CTA performed at 1 and 6 months demonstrated
endoleak obliteration and no growth of the aneurysm.
DISCUSSION
Transarterial embolization (TAE) treatment of T2E
frequently fails because the endoleak behaves like an arterio-
venous malformation whereby embolization of one branch
inevitably leads to hypertrophy or recruitment of another
with persistence of the endoleak.7 This is potentially why
failure rates of TAE are as high as 80%.1-3,8 Several methods
of direct aneurysm sac access have been described, including
translumbar, percutaneous/laparoscopic transperitoneal, and
transcaval methods. Advantages of TCE include utilization
of supine positioning, which facilitates patient comfort and
concomitant arterial access. This allows conﬁrmation of
the type of endoleak, concurrent TAE if necessary, and veri-
ﬁcation of endoleak obliteration. Furthermore, with TCE,
the IVC is punctured through one wall instead of both, as
required when the right translumbar/transcaval approach
is performed, and lower risk of retroperitoneal hemorrhage
or inadvertent bowel injury may be anticipated.6
Table I. Patient demographics, previous endovascular aneurysm repair, attempted embolizations, and transcaval
embolization procedural details
Patient
Age,
years Comorbidities EVAR device
Time since
EVAR, months
No. prior
embolizations
Aneurysm diameter
growth, mm
1 83 CAD, tobacco, prior TAA repair LeMaitre AUI 43 0 20
2 85 CAD, DM, HTN, HLD AneuRx 93 1 18
3 57 HTN, HLD, COPD TCook, Zenith 20 0 16
4 75 DM, HTN, COPD Cook, Zenith 17 1 7
5 64 CAD, DM, HTN, COPD Cook, Zenith 61 0 9
6 72 CAD, HTN, HLD, COPD Gore excluder 98 1 37
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EVAR, endovascular aneurysm repair; HLD, hyper-
lipidemia; HTN, hypertension; NA, not applicable; TAA, thoracic aortic aneurysm; TCE, transcaval embolization.
Patient demographics, comorbidities, and procedure-related details regarding prior endovascular repair, aneurysm growth due to endoleak, and previous
embolization attempts are given. Transcaval embolization procedure-speciﬁc details, including contrast exposure, estimated blood loss, ﬂuoroscopy and
procedural times, and procedure-speciﬁc outcome data, also are given.
aCoils used were Cook Medical (Bloomington, Ind) stainless steel or Terumo Medical (Somerset, NJ) retrievable 0.018- or 0.035-inch AZUR framing coils or
HydroCoils.
Fig 3. Algorithm demonstrating our current treatment paradigm for type II endoleaks, with an emphasis on delivering
coils directly to the excluded abdominal aortic aneurysm sac. CT, Computed tomography; EL, endoleak; IMA, inferior
mesenteric artery; IVC, inferior vena cava; SMA, superior mesenteric artery.
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different techniques, it is more useful to appreciate that
these remedial strategies are complementary. Our treat-
ment algorithm depends on the source and location of
the endoleak and is predicated on the philosophy that the
embolant must be delivered directly to the aneurysm sac
(Fig 3). If the endoleak emanates from the inferior mesen-
teric artery and there is direct communication to the supe-
rior mesenteric artery, we preferentially attempt initial
management using transsuperior mesenteric artery emboli-
zation. If the endoleak originates from a lumbar or middle
sacral vessel, we directly access the aorta via either a trans-
lumbar or a transcaval approach, with the approach
dictated by the location of the endoleak and the aorta rela-
tive to the IVC and lumbar spine.The technical and clinical outcomes of the various trans-
catheter T2E management strategies are listed in Table II.
All forms of transcatheter therapies have been reported to
achieve high rates of technical success. However, deﬁnitions
of “clinical success” in the reports are heterogeneous, with
many stating that success is absence of measured increase
in aneurysm diameter or reintervention. If a more strict deﬁ-
nition is used, whereby success is deﬁned as absence of aneu-
rysm growth, reintervention, plus elimination of endoleak,
the cumulative combined reported success of transarterial
and translumbar procedures is #70%. This is comparable
to the early results of TCE.
Limitations of this report are that it is a small series of
highly selected patients with no comparative alternative
management strategy. The inherent selection bias and
Contrast, mL
Fluoroscopy time,
minutes EBL, mL
Total procedural
time, minutes TCE embolanta Clinical success
NA 24 20 79 Framing coil 9 Y
125 22 25 61 Framing coil 4, HydroCoil 2 N
NA 21 20 52 Stainless steel coil 4, framing coil 2 Y
115 26 20 121 Stainless steel coil 10, framing coil 2,
HydroCoil 1, thrombin
N
45 23 25 84 Framing coil 7 Y
45 26 15 109 Stainless steel coil 2, framing coil 1 Y
Table II. Technical and clinical outcomes of the various transcatheter therapies for type II endoleak after EVAR
Approach Author No. of patients Technical success, % Clinical success, % Reintervention, % Follow-up time, monthsb
Transcaval
Mansueto6 12 92 83 NS 12
Scali (present study) 6 100 67 17 8
Cumulative 96 75 0-17
Transarterial
Baum2 8 88 NS NS NS
Görich1 11 100 100 0 25
Haulon11,a 18 94 89 0 13
Baum4 20 90 20 45 14
Solis9 10 90 40 20 NS
Kasirajan12,a 8 75 75 0 9
Becquemin10 33 66 NS
Stavropoulos13,a 23 96 78 13 17
Nevala14,a 10 40 22 33 NS
Massis15,a 65 66 59 NS 4
Cumulative 82 60 0-45
Translumbar
Baum2 7 100 100 0 5
Baum4 13 100 92 NS 9
Stavropoulos13,a 9 100 67 33 14
Stavropoulos13,a 62 100 73 16 20
Nevala14,a 3 100 67 33 NS
Massis15,a 36 100 75 NS 4
Cumulative 100 79 0-33
Comparative descriptions of the technical and clinical outcomes of the reported series for transcaval, transarterial (including superior mesenteric artery-inferior
mesenteric artery), and translumbar embolization procedures are given.
EVAR, Endovascular aortic repair; NS, not speciﬁed.
aTranslumbar transcaval approach.
bFollow-up time is set or averaged interval from time of embolization procedure.
Table I. Continued.
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patient numbers and/or prospectively randomized validation.
Although no complications occurred, multiple potential
complicationsofTCEinclude inadvertent intracaval emboliza-
tion of coils, retroperitoneal hemorrhage, unintentional punc-
ture of the existing endograft leading to type III endoleak,
injury to periaortic/caval structures, and aortocaval ﬁstulas.CONCLUSIONS
The TCE appears to be a safe and technically feasible
management option for treatment of persistent T2E. In this
small case series, the technical and clinical success rates of
TCE are comparable to those of other reported treatment
strategies. Thus, TCE provides a complementary technique
to existing methods of endoleak management.
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